Biolinerx Ltd., of Tel Aviv, Israel, initiated a phase IIb trial of BL-8040 as a consolidation treatment for acute myeloid leukemia (AML). The study will examine BL-8040 as part of a second stage treatment to improve outcomes for AML patients who achieved remission following induction therapy.